MyOme Launches Integrated Polygenic Risk Score for Prostate Cancer
The whole-genome test combines data from 7 million genetic markers with clinical risk factors to provide individualized 10-year and lifetime risk assessments.
The whole-genome test combines data from 7 million genetic markers with clinical risk factors to provide individualized 10-year and lifetime risk assessments.
Decipher Prostate Genomic Classifier data is included in a new SEER Program database, enabling the study of prostate cancer outcomes.
A new prostate cancer screening method could help better predict which patients need to undergo a biopsy, reducing unnecessary procedures.
The new urine-based test aims to differentiate between slow-growing and aggressive forms of prostate cancer.
Read MoreA study found an active surveillance blood test for prostate cancer could predict whether a patient had indolent or aggressive disease.
Read MoreA study investigating a single invitation to a PSA blood test to screen for prostate cancer found it had a small impact on reducing deaths.
Read MoreMRI of the prostate, combined with a blood test, can help find if a prostate lesion is clinically significant cancer, new research suggests.
Read MoreResearchers developed a deep-learning model to improve the 3D segmentation of glandular tissue structures for prostate cancer assessment.
Read MoreAI has helped scientists reveal a new form of aggressive prostate cancer which could revolutionize how the disease is diagnosed in the future.Â
Read MoreOncobiomix says it will use Limmi’s Disease Insights Platform to power their AI models for predicting prostate cancer risk.
Read MorePathologists at OSUCCC-James have been evaluating an AI algorithm for the past year. The results are extremely promising.
Read MoreA new study has found that rectal examination has no advantages over the PSA blood test for detecting prostate cancer.
Read MoreResearchers have developed a blood test that can reliably detect NEPC and differentiate it from CRPC-adenocarcinoma.
Read MoreArteraAI says the CMS decided on the payment rate for the ArteraAI Prostate Test, a clinical diagnostic laboratory test for prostate cancer.
Read MoreUCLA Researchers have received a five-year, $3 million grant to develop AI that can detect and predict aggressive prostate cancer.
Read MoreMen with biomarker HSD3B1 may exhibit resistance to combined radiation and hormone therapy for prostate cancer.Â
Read MoreBlack men are more likely to develop prostate cancer than white men and more likely to have advanced disease and to die than white men.Â
Read MoreArteraAI will present data demonstrating the successful validation of its prognostic model in advanced prostate cancer.
Read More